Bladder Cancer

Pembrolizumab Demonstrated Complete Responses in Non-Muscle Invasive Bladder Cancer

August 03, 2020

The immune checkpoint inhibitor pembrolizumab appeared well-tolerated with encouraging antitumor activity as treatment of patients with non-muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guerin, according to the updated follow-up from the phase 2 KEYNOTE-057 clinical trial.

Pembrolizumab Plus Nab-Paclitaxel May Be an Option for Switch Maintenance Following Chemo in mUC

July 29, 2020

The combination of pembrolizumab plus nab-paclitaxel demonstrated clinically meaningful and sustainable responses, along with prolonged progression-free survival when administered as salvage therapy to patients with metastatic urothelial carcinoma.

Bladder EpiCheck Demonstrates Accuracy for Detection of Urothelial Carcinoma Recurrence

July 20, 2020

“Accurately identifying patients with high-grade UTUC is critical, as the disease progression can be deadly and the standard treatment – removal of ureter and kidney – leads to major morbidity."

Discussing Recent Advances and Clinical Trials in Bladder Cancer

July 13, 2020

Matthew Galsky, MD, discusses the most recent data in patients with bladder cancer.

The Addition of Frontline Maintenance Avelumab Improves OS in Urothelial Carcinoma

July 13, 2020

In an interview with Targeted Oncology, Petros Grivas, MD, PhD, discussed the findings from the phase 3 JAVELIN Bladder 100 study, which evaluated the addition of avelumab to best supportive care in patients with locally advanced, unresectable or metastatic urothelial cancer.

JAVELIN Bladder 100 Trial Impresses, Ensures Patients Have Access to Second-Line Immunotherapy at Disease Progression

July 07, 2020

Results from the study, JAVELIN Bladder 100, demonstrated that in patients who have achieved stable disease or better after first-line platinum-based chemotherapy, maintenance avelumab significantly improved both progression-free survival and overall survival compared with best supportive care alone.

Avelumab Plus Best Supportive Care Shows Efficacy in Urothelial Carcinoma

June 24, 2020

Petros Grivas, MD, PhD, discusses the JAVELIN Bladder 100 trial of maintenance avelumab plus best supportive care versus best supportive care alone after platinum-based first-line chemotherapy in patients with advanced urothelial carcinoma.

Significant Benefit Not Seen With Frontline Pembrolizumab and Chemo for Advanced Urothelial Carcinoma

June 10, 2020

"While we are disappointed in these study results, Keytruda has been established as an important option in the treatment of metastatic bladder cancer, and we are committed to continuing our research to help more patients with this disease."

Infigratinib Active in Multiple Settings of Urothelial Cancer

June 03, 2020

"Our data suggests similar activity of infigratinib in patients receiving it in the first-line setting versus subsequent lines for advanced urothelial carcinoma."